Review



factor 1 hif 1 α  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc factor 1 hif 1 α
    Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).
    Factor 1 Hif 1 α, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1461 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/factor 1 hif 1 α/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1461 article reviews
    factor 1 hif 1 α - by Bioz Stars, 2026-02
    97/100 stars

    Images

    1) Product Images from "Uncovering the anticancer effects of Bhallataka Taila in lung cancer: A metabolomic and network pharmacology approach"

    Article Title: Uncovering the anticancer effects of Bhallataka Taila in lung cancer: A metabolomic and network pharmacology approach

    Journal: BioImpacts

    doi: 10.34172/bi.30568

    Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).
    Figure Legend Snippet: Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).

    Techniques Used: Expressing, Control

    Fig. 7. Gene expression profiling of (A) BAX (B) Bcl2 (C) HIF-1α (D) p53 (E) MMP-2 (F) MMP-9 in A549 cells exposed to Bhallataka taila and cisplatin as analyzed using qRT-PCR. (* P < 0.05, ** P < 0.01, relative to control, # P < 0.005, relative to cisplatin).
    Figure Legend Snippet: Fig. 7. Gene expression profiling of (A) BAX (B) Bcl2 (C) HIF-1α (D) p53 (E) MMP-2 (F) MMP-9 in A549 cells exposed to Bhallataka taila and cisplatin as analyzed using qRT-PCR. (* P < 0.05, ** P < 0.01, relative to control, # P < 0.005, relative to cisplatin).

    Techniques Used: Gene Expression, Quantitative RT-PCR, Control



    Similar Products

    hif1 α  (Bioss)
    95
    Bioss hif1 α
    (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) <t>HIF1</t> <t>α</t> staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.
    Hif1 α, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hif1 α/product/Bioss
    Average 95 stars, based on 1 article reviews
    hif1 α - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    hif 1 α inhibitor yc 1  (MedChemExpress)
    95
    MedChemExpress hif 1 α inhibitor yc 1
    (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) <t>HIF1</t> <t>α</t> staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.
    Hif 1 α Inhibitor Yc 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hif 1 α inhibitor yc 1/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    hif 1 α inhibitor yc 1 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    hif 1 α  (Proteintech)
    93
    Proteintech hif 1 α
    (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) <t>HIF1</t> <t>α</t> staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.
    Hif 1 α, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hif 1 α/product/Proteintech
    Average 93 stars, based on 1 article reviews
    hif 1 α - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    hif 1 α inhibitors  (MedChemExpress)
    93
    MedChemExpress hif 1 α inhibitors
    (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) <t>HIF1</t> <t>α</t> staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.
    Hif 1 α Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hif 1 α inhibitors/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    hif 1 α inhibitors - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    pe anti hif1 α  (Bioss)
    94
    Bioss pe anti hif1 α
    (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) <t>HIF1</t> <t>α</t> staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.
    Pe Anti Hif1 α, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti hif1 α/product/Bioss
    Average 94 stars, based on 1 article reviews
    pe anti hif1 α - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    factor 1 hif 1 α  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc factor 1 hif 1 α
    Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).
    Factor 1 Hif 1 α, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/factor 1 hif 1 α/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    factor 1 hif 1 α - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    hif 1 α  (MedChemExpress)
    94
    MedChemExpress hif 1 α
    Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).
    Hif 1 α, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hif 1 α/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    hif 1 α - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    hif 1 α selective inhibitor kc7f2  (Selleck Chemicals)
    95
    Selleck Chemicals hif 1 α selective inhibitor kc7f2
    Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).
    Hif 1 α Selective Inhibitor Kc7f2, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hif 1 α selective inhibitor kc7f2/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    hif 1 α selective inhibitor kc7f2 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) HIF1 α staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.

    Journal: PeerJ

    Article Title: UBE2S and HIF1α expression patterns and stratified analysis reveal prognostic value in esophageal squamous cell carcinoma

    doi: 10.7717/peerj.20694

    Figure Lengend Snippet: (A–D) UBE2S staining intensities: negative, weak, moderate, strong. (E) UBE2S IHC scores ( p < 0.001). (F–I) HIF1 α staining intensities: negative, weak, moderate, strong. (J) HIF1 α IHC scores ( p = 0.004). (K–N) p110 α staining intensities: negative, weak, moderate, strong. (O) p110 α IHC scores ( p = 0.039). All micrographs shown at ×200 magnification.

    Article Snippet: The primary antibodies used were: UBE2S (rabbit polyclonal, 14115-1-AP, 1:360; Proteintech), HIF1 α (rabbit monoclonal, bs-0737R, 1:400; BIOSS), and p110 α (rabbit polyclonal, C73F8, 1:250; ZSGB-Bio).

    Techniques: Staining

    (A, B) Pan-cancer mRNA expression analysis of UBE2S (A) and HIF1 α (B) across TCGA malignancies, indicating significant overexpression in ESCA. (C, D) Validation of UBE2S (C) and HIF1 α (D) mRNA overexpression in the TCGA-ESCA tumor cohort compared to a pooled normal tissue reference (integrating GTEx data; p < 0.001, Wilcoxon rank-sum test). (E, F) Independent validation in the GEO dataset ( GSE161533 ) confirms significant overexpression of UBE2S (E) and HIF1 α (F) in ESCC tissues compared to paired adjacent non-tumorous tissues ( p < 0.001). (G) Correlation analysis within the TCGA-ESCA cohort reveals a significant positive correlation between UBE2S and HIF1 α mRNA expression levels (Pearson’s correlation; R = 0.42, p = 0.0013).

    Journal: PeerJ

    Article Title: UBE2S and HIF1α expression patterns and stratified analysis reveal prognostic value in esophageal squamous cell carcinoma

    doi: 10.7717/peerj.20694

    Figure Lengend Snippet: (A, B) Pan-cancer mRNA expression analysis of UBE2S (A) and HIF1 α (B) across TCGA malignancies, indicating significant overexpression in ESCA. (C, D) Validation of UBE2S (C) and HIF1 α (D) mRNA overexpression in the TCGA-ESCA tumor cohort compared to a pooled normal tissue reference (integrating GTEx data; p < 0.001, Wilcoxon rank-sum test). (E, F) Independent validation in the GEO dataset ( GSE161533 ) confirms significant overexpression of UBE2S (E) and HIF1 α (F) in ESCC tissues compared to paired adjacent non-tumorous tissues ( p < 0.001). (G) Correlation analysis within the TCGA-ESCA cohort reveals a significant positive correlation between UBE2S and HIF1 α mRNA expression levels (Pearson’s correlation; R = 0.42, p = 0.0013).

    Article Snippet: The primary antibodies used were: UBE2S (rabbit polyclonal, 14115-1-AP, 1:360; Proteintech), HIF1 α (rabbit monoclonal, bs-0737R, 1:400; BIOSS), and p110 α (rabbit polyclonal, C73F8, 1:250; ZSGB-Bio).

    Techniques: Expressing, Over Expression, Biomarker Discovery

    (A, B) Kaplan–Meier survival curves showing that high expression of UBE2S is significantly associated with poorer overall survival (OS; p = 0.006) and progression-free survival (PFS; p = 0.034). (C, D) Similarly, high expression of HIF1 α is associated with reduced OS ( p < 0.001) and PFS ( p = 0.002). (E, F) Patients were stratified into four groups based on UBE2S and HIF1 α co-expression status: Group 1 (dual-negative), Group 2 (UBE2S-negative/HIF1 α -positive), Group 3 (UBE2S-positive/HIF1 α -negative), and Group 4 (dual-positive). Kaplan–Meier analysis revealed significant stratification of both OS ( p < 0.001) and PFS ( p = 0.005) among these groups, with patients exhibiting dual-positive expression (Group 4) demonstrating the poorest outcomes.

    Journal: PeerJ

    Article Title: UBE2S and HIF1α expression patterns and stratified analysis reveal prognostic value in esophageal squamous cell carcinoma

    doi: 10.7717/peerj.20694

    Figure Lengend Snippet: (A, B) Kaplan–Meier survival curves showing that high expression of UBE2S is significantly associated with poorer overall survival (OS; p = 0.006) and progression-free survival (PFS; p = 0.034). (C, D) Similarly, high expression of HIF1 α is associated with reduced OS ( p < 0.001) and PFS ( p = 0.002). (E, F) Patients were stratified into four groups based on UBE2S and HIF1 α co-expression status: Group 1 (dual-negative), Group 2 (UBE2S-negative/HIF1 α -positive), Group 3 (UBE2S-positive/HIF1 α -negative), and Group 4 (dual-positive). Kaplan–Meier analysis revealed significant stratification of both OS ( p < 0.001) and PFS ( p = 0.005) among these groups, with patients exhibiting dual-positive expression (Group 4) demonstrating the poorest outcomes.

    Article Snippet: The primary antibodies used were: UBE2S (rabbit polyclonal, 14115-1-AP, 1:360; Proteintech), HIF1 α (rabbit monoclonal, bs-0737R, 1:400; BIOSS), and p110 α (rabbit polyclonal, C73F8, 1:250; ZSGB-Bio).

    Techniques: Expressing

    Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).

    Journal: BioImpacts

    Article Title: Uncovering the anticancer effects of Bhallataka Taila in lung cancer: A metabolomic and network pharmacology approach

    doi: 10.34172/bi.30568

    Figure Lengend Snippet: Fig. 6. (A) Expression of indicated proteins in A549 lung adenocarcinoma cells treated with Bhallataka taila and cisplatin. Beta-actin served as the loading control. Densitometry graph showing the levels of (B) p-ERK (C) HIF-1α (D) Ki-67, and (E) p53 in lung cancer cells (* P < 0.05, ** P < 0.01, *** P < 0.001, relative to control, ## P < 0.01, ### P < 0.001, relative to cisplatin).

    Article Snippet: Antibodies against total and phosphoextracellular signal-regulated kinase (pERK) (T202/ Y204), beta-actin, hypoxia-inducible factor 1 (HIF-1) α, and p53 were obtained from Cell Signaling Technology.

    Techniques: Expressing, Control

    Fig. 7. Gene expression profiling of (A) BAX (B) Bcl2 (C) HIF-1α (D) p53 (E) MMP-2 (F) MMP-9 in A549 cells exposed to Bhallataka taila and cisplatin as analyzed using qRT-PCR. (* P < 0.05, ** P < 0.01, relative to control, # P < 0.005, relative to cisplatin).

    Journal: BioImpacts

    Article Title: Uncovering the anticancer effects of Bhallataka Taila in lung cancer: A metabolomic and network pharmacology approach

    doi: 10.34172/bi.30568

    Figure Lengend Snippet: Fig. 7. Gene expression profiling of (A) BAX (B) Bcl2 (C) HIF-1α (D) p53 (E) MMP-2 (F) MMP-9 in A549 cells exposed to Bhallataka taila and cisplatin as analyzed using qRT-PCR. (* P < 0.05, ** P < 0.01, relative to control, # P < 0.005, relative to cisplatin).

    Article Snippet: Antibodies against total and phosphoextracellular signal-regulated kinase (pERK) (T202/ Y204), beta-actin, hypoxia-inducible factor 1 (HIF-1) α, and p53 were obtained from Cell Signaling Technology.

    Techniques: Gene Expression, Quantitative RT-PCR, Control